Abstract Drug-resistant tuberculosis is a serious global health threat. Bedaquiline (BDQ) is a relatively new core drug, targeting the respiratory chain in Mycobacterium tuberculosis (Mtb). While mutations in the BDQ target gene, atpE, are rare in clinical isolates, mutations in the Rv0678 gene, a transcriptional repressor regulating the efflux pump MmpS5-MmpL5, are increasingly observed, and have been linked to worse treatment outcomes. Nevertheless, underlying mechanisms of (cross)-resistance remain incompletely resolved. Our study aims to distinguish resistance associated variants from other polymorphisms, by assessing the in vitro onset of mutations under drug pressure, combined with their impact on minimum inhibitory concentrations (MI...
Bedaquiline, clofazimine and linezolid are pertinent drugs for drug-resistant tuberculosis. Drug-res...
Bedaquiline, clofazimine and linezolid are pertinent drugs for drug-resistant tuberculosis. Drug-res...
Clinical resistance against Bedaquiline, the first new anti-tuberculosis compound with a novel mecha...
Background: Bedaquiline is a core drug for the treatment of multidrug-resistant tuberculosis; howeve...
Background: Bedaquiline is a core drug for the treatment of multidrug-resistant tuberculosis; howeve...
Background: Bedaquiline is a core drug for the treatment of multidrug-resistant tuberculosis; howeve...
Abstract Background Mutations in the Rv0678, pepQ and atpE genes of Mycobacterium tuberculosis (MTB)...
Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment of mult...
Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment of mult...
Tuberculosis (TB) is one of the major causes of death related to antimicrobial resistance worldwide ...
Bedaquiline resistance within Mycobacterium tuberculosis may arise through efflux-based (rv0678) or ...
<div><p>Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment...
Bedaquiline, clofazimine and linezolid are pertinent drugs for drug-resistant tuberculosis. Drug-res...
Bedaquiline, clofazimine and linezolid are pertinent drugs for drug-resistant tuberculosis. Drug-res...
Bedaquiline, clofazimine and linezolid are pertinent drugs for drug-resistant tuberculosis. Drug-res...
Bedaquiline, clofazimine and linezolid are pertinent drugs for drug-resistant tuberculosis. Drug-res...
Bedaquiline, clofazimine and linezolid are pertinent drugs for drug-resistant tuberculosis. Drug-res...
Clinical resistance against Bedaquiline, the first new anti-tuberculosis compound with a novel mecha...
Background: Bedaquiline is a core drug for the treatment of multidrug-resistant tuberculosis; howeve...
Background: Bedaquiline is a core drug for the treatment of multidrug-resistant tuberculosis; howeve...
Background: Bedaquiline is a core drug for the treatment of multidrug-resistant tuberculosis; howeve...
Abstract Background Mutations in the Rv0678, pepQ and atpE genes of Mycobacterium tuberculosis (MTB)...
Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment of mult...
Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment of mult...
Tuberculosis (TB) is one of the major causes of death related to antimicrobial resistance worldwide ...
Bedaquiline resistance within Mycobacterium tuberculosis may arise through efflux-based (rv0678) or ...
<div><p>Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment...
Bedaquiline, clofazimine and linezolid are pertinent drugs for drug-resistant tuberculosis. Drug-res...
Bedaquiline, clofazimine and linezolid are pertinent drugs for drug-resistant tuberculosis. Drug-res...
Bedaquiline, clofazimine and linezolid are pertinent drugs for drug-resistant tuberculosis. Drug-res...
Bedaquiline, clofazimine and linezolid are pertinent drugs for drug-resistant tuberculosis. Drug-res...
Bedaquiline, clofazimine and linezolid are pertinent drugs for drug-resistant tuberculosis. Drug-res...
Clinical resistance against Bedaquiline, the first new anti-tuberculosis compound with a novel mecha...